Dengue-Immune Humans Have Higher Levels of Complement-Independent Enhancing Antibody than Complement-Dependent Neutralizing Antibody

Atsushi Yamanaka1,2,3* and Eiji Konishi1,2,3

1 BIKEN Endowed Department of Dengue Vaccine Development, Faculty of Tropical Medicine, Mahidol University, Bangkok; 2 BIKEN Endowed Department of Dengue Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871; and 3 Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan

SUMMARY: Dengue is the most important arboviral disease worldwide. We previously reported that most inhabitants of dengue-endemic countries who are naturally immune to the disease have infection-enhancing antibodies whose in vitro activity does not decrease in the presence of complement (complement-independent enhancing antibodies, or CiEAb). Here, we compared levels of CiEAb and complement-dependent neutralizing antibodies (CdNAb) in dengue-immune humans. A typical antibody dose-response pattern obtained in our assay system to measure the balance between neutralizing and enhancing antibodies showed both neutralizing and enhancing activities depending on serum dilution factor. The addition of complement to the assay system increased the activity of neutralizing antibodies at lower dilutions, indicating the presence of CdNAb. In contrast, similar dose-response curves were obtained with and without complement at higher dilutions, indicating higher levels of CiEAb than CdNAb. For experimental support for the higher CiEAb levels, a cocktail of mouse monoclonal antibodies against dengue virus type 1 was prepared. The antibody dose-response curves obtained in this assay, with or without complement, were similar to those obtained with human serum samples when a high proportion of D1-V-3H12 (an antibody exhibiting only enhancing activity and thus a model for CiEAb) was used in the cocktail. This study revealed higher-level induction of CiEAb than CdNAb in humans naturally infected with dengue viruses.

Received August 24, 2016. Accepted February 27, 2017.
J-STAGE Advance Publication March 28, 2017.
DOI: 10.7883/yoken.JJID.2016.379
*Corresponding author: Mailing address: BIKEN Endowed Department of Dengue Vaccine Development, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand. Tel: +66-2-354-5981, Fax: +66-2-255-8377, E-mail: kmmya@biken.osaka-u.ac.jp

Tropical Medicine, Mahidol University. Before the antibody assays, the sera were heat-inactivated at 56°C for 30 min. Mouse monoclonal antibodies (MAbs) against DENV-1 (D1-IV-7F4, D1-V-3H12) have been reported (14). Another MAb against DENV-1 (D1-IV-1C8) was obtained when the MAbs described above were generated. The balance between the enhancing and neutralizing activities was measured in semi-adherent K562 cells, as previously described (15). Briefly, serial dilutions of antibody specimens were mixed with DENV-1 (Mochizuki strain) in the absence or presence of 5% rabbit complement, and then incubated at 37°C for 2 h. K562 cells were then added and incubated at 37°C for 2 days. After fixation and immunostaining, the numbers of infected cells were counted. The cut-off values for the enhancing and neutralizing activities were calculated as the means ± 3SD of 8 negative controls, adjusted for approximately 100 infected cells.

The leftmost lower panel of Fig. 1A shows the typical dose-dependent neutralizing and enhancing antibody activity patterns observed in dengue-immune human serum (I#230) in our assay system, with and without complement. This sample displayed neutralizing, enhancing, and no activities at low, medium, and high serum dilutions, respectively. Addition of complement to the assay system reduced the infected cell counts at dilutions of 1:10 to 1:2,560, but not at 1:10,240 to 1:163,840, indicating that the activity level of the complement-independent antibody was higher than that of complement-dependent antibody.

The other lower panels of Fig. 1A show the dose-dependent antibody activity patterns observed with 2 more
dengue-immune human sera (I#834 and I#333). These samples showed dose-response curves equivalent to a portion of the curve obtained for I#230, at dilutions of 1:160 or higher for I#834, and 1:2,560 or higher for I#333. Because the waning of neutralizing antibodies is hypothesized to be a mechanism by which dengue viral infection is enhanced (8), the patterns of I#834 and I#333 may be attributable to antibody waning compared to the pattern of I#230. In our previous study using 94 dengue-immune humans (12), we found that neutralizing activity in humans was exhibited only by CdNAb, and not by complement-independent antibodies. Furthermore, although complement-dependent enhancing antibody activities were also observed (e.g., 1:40 dilution of I#834), they always appeared at higher dilutions than those at which complement-dependent neutralizing activities were observed (e.g., 1:10 dilution of I#834). Thus, we regarded complement-dependent antibody as CdNAb, while complement-independent antibody CiEAb. Because these 3 dose-response patterns were generally observed in sera from dengue-immune humans (12), our results suggest that CiEAb is induced at higher levels than CdNAb in these subjects.

Another method we used to determine the proportion of CiEAb in dengue-immune human sera involved the preparation of a MAb cocktail used to mimic the human antibody dose-dependent activity patterns. The cocktail was composed of 3H12 (an enhancing-only antibody and thus a model for CiEAb), 7F4 (a neutralizing-only antibody), and 1C8 (CdNAb; Fig. 1B). When these MAbs were adjusted to an IgG concentration of 1 mg/ml and mixed in a specific ratio (3H12:7F4:1C8 = 8,000:1:2,000), the dose-response curves obtained in the assay, with or without complement (Fig. 1A: upper panel), were similar to those obtained with human serum samples (Fig. 1A: lower panels). The first step in determining this mixing ratio was to mix various ratios of 1C8 to 3H12 (Fig. 1C). Because mouse MAbs with both neutralizing and enhancing activities usually do not show enhancing activity in the presence of complement, the addition of the enhancing-only antibody was required to reproduce the dose-response patterns characteristic of dengue-immune human sera, in which complement-independent enhancing activities were observed in the high-dilution range. We selected a 3H12:1C8 ratio of 8:2 and then combined this mixture with 7F4 in varying ratios to adjust the neutralizing activity at low dilutions. From the dose-response curves (Fig. 1D), we selected a 3H12 + 1C8:7F4 ratio of 10,000:1, because ratios of 10:1–1,000:1 did not maintain the dose-response patterns characteristic of complement-independent enhancing activity at high dilutions. The mixing ratio of the MAbs in the antibody cocktail that mimicked the dose-response patterns of dengue-immune human sera suggested that a 3H12-like antibody was predominant in the sera. This result supports the presence of a high proportion of CiEAb in dengue-immune human sera.

In conclusion, this study revealed that natural infection with DENVs in humans induces CiEAb more than CdNAb. Although the serotype that had infected the dengue-immune people in this study is unknown, dose-dependent neutralizing and enhancing antibody activity patterns obtained in our assay system were similar,
Complement-Independent Enhancing Antibody to DENV

irrespective of the infecting serotype (12,16). Because of the difference between humans and mice and the presence of various antibodies in polyclonal status, further studies are needed using a sufficient number of human MAbs. Recently, we found an inhibitory effect of CiEAb on the neutralizing activity of CdNAb (17), suggesting that concomitant induction of CiEAb suppresses the protective effect of CdNAb in vivo. Thus, further studies are also needed examining this aspect. These findings have implications for dengue vaccine development, because the currently licensed dengue vaccines are created from antigens derived from viral strains isolated from nature.

Acknowledgments We thank Ms. Yuko Tabuchi for her technical assistance. This work was supported by a grant from Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan to Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.

Conflict of interest None to declare.

REFERENCES
1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496:504-7.
2. Halstead SB. Dengue. Lancet. 2007;370:1644-52.
3. Guzman MG, Harris E. Dengue. Lancet. 2015;385:453-65.
4. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358-65.
5. Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372:113-23.
6. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1193-206.
7. Halstead SB, O’Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265:739-41.
8. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421-67.
9. Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med. 2008;10:e12.
10. Mehlhop E, Ansarah-Sobrinho C, Johnson S, et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe. 2007;2:417-26.
11. Yamanaka A, Kosugi S, Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol. 2008;82:927-37.
12. Yamanaka A, Tabuchi Y, Mulyatno KC, et al. Dengue virus infection-enhancing and neutralizing antibody balance in children of the Philippines and Indonesia. Microbes Infect. 2012;14:1152-9.
13. Konishi E, Houki Y, Harano K, et al. High prevalence of antibody to Toxoplasma gondii among humans in Surabaya, Indonesia. Jpn J Infect Dis. 2000;53:238-41.
14. Yamanaka A, Kotaki T, Konishi E. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. J Virol. 2013;87:12828-37.
15. Konishi E, Tabuchi Y, Yamanaka A. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods. 2010;163:360-7.
16. Yamanaka A, Oddgun D, Chantawat N, et al. Dengue virus infection-enhancing antibody activities against Indonesian strains in inhabitants of central Thailand. Microbes Infect. 2016;18:277-84.
17. Yamanaka A, Konishi E. Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity. Vaccine. 2016;34:6449-57.